CBO Agrees To Seek New Data On How IRA Affects Drug Innovation

The Congressional Budget Office (CBO) is heeding calls from House Budget Committee Republicans to gather new data on how the Inflation Reduction Act’s price control policies are affecting pharmaceutical innovation. CBO Director Phillip Swagel in a blog post published Wednesday (Dec. 20) said the agency could benefit from new information on how the changes drug companies are expected to see in their future profits will affect the development of drugs with differing characteristics, such as the impact on small molecule...